GLEEVEC
Total Payments
$33.5M
Transactions
384
Doctors
69
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.6M | 18 | 5 |
| 2023 | $3.1M | 16 | 0 |
| 2022 | $3.6M | 9 | 0 |
| 2021 | $5.0M | 10 | 0 |
| 2020 | $2.4M | 58 | 23 |
| 2019 | $6.5M | 225 | 46 |
| 2018 | $6.0M | 13 | 0 |
| 2017 | $5.3M | 35 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $33.2M | 108 | 99.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,715 | 50 | 0.5% |
| Royalty or License | $100,000 | 2 | 0.3% |
| Travel and Lodging | $35,809 | 98 | 0.1% |
| Consulting Fee | $31,574 | 12 | 0.1% |
| Food and Beverage | $9,975 | 114 | 0.0% |
Payments by Type
Research
$33.2M
108 transactions
General
$342,073
276 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN LABEL MULTI CENTER IMATINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED IMATINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED IMATINIB TREATMENT | Novartis Pharmaceuticals Corporation | $27.9M | 0 |
| An open label multi center imatinib rollover protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment | Novartis Pharmaceuticals Corporation | $4.7M | 0 |
| LAM PILOT STUDY WITH IMATINIB MESYLATE LAMP1 | Novartis Pharmaceuticals Corporation | $435,264 | 0 |
| A PHASE II NON RANDOMIZED OPEN LABEL MULTICENTER STUDY OF 5 YEAR ADJUVANT IMATINIB MESYLATE GLEEVEC IN PATIENTS AT SIGNIFICANT RISK FOR RECURRENCE FOLLOWING COMPLETE RESECTION OF PRIMARY GASTROINTESTINAL STROMAL TUMOR GIST | Novartis Pharmaceuticals Corporation | $118,005 | 0 |
| A MULTI ARM DOSE FINDING PHASE IB MULTICENTER STUDY OF IMATINIB IN COMBINATION WITH THE ORAL PHOSPHATIDYL INOSITOL 3 KINASE PI3 K INHIBITOR BKM120 IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR GIST WHO FAILED PRIOR THERAPY WITH IMATINIB AND SUNITINIB | Novartis Pharmaceuticals Corporation | $73,726 | 0 |
| A PHASE III STUDY OF STI571 VERSUS INTERFERON ALPHA IFN ALPHA COMBINED WITH CYTARABINE ARA C IN PATIENTS WITH NEWLY DIAGNOSED PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP | Novartis Pharmaceuticals Corporation | $4,095 | 0 |
| A DOSE FINDING PHASE IB MULTICENTER STUDY OF IMATINIB INCOMBINATION WITH THE ORAL PHOSPHATIDYL INOSITOL 3 KINASEPI3K INHIBITOR BYL719 IN PATIENTS WITH GASTROINTESTINALSTROMAL TUMOR GIST WHO FAILED PRIOR THERAPY WITH IMATINIBAND SUNITINIB | Novartis Pharmaceuticals Corporation | $3,800 | 0 |
Top Doctors Receiving Payments for GLEEVEC — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Sandy Springs, GA | $125.00 | 1 |
| , MD | Anatomic Pathology & Clinical Pathology | Miami, FL | $124.99 | 1 |
| , M.D | Hematology & Oncology | San Antonio, TX | $124.99 | 1 |
| , M.D | Medical Oncology | Dallas, TX | $123.53 | 1 |
| , M.D | Medical Oncology | Dallas, TX | $123.53 | 1 |
| , M.D | Internal Medicine | Mobile, AL | $123.50 | 1 |
| , MD | Hematology & Oncology | Houston, TX | $122.08 | 1 |
| , MD | Hematology & Oncology | Webster, TX | $122.08 | 1 |
| , M.D | Specialist | Glendale, AZ | $122.06 | 1 |
| , MD | Hematology & Oncology | Southfield, MI | $121.84 | 1 |
| , MD | Hematology & Oncology | Troy, MI | $121.84 | 1 |
| , M.D | Hematology & Oncology | Rochester, MI | $121.84 | 1 |
| , DO | Hematology & Oncology | Southfield, MI | $121.84 | 1 |
| , D.O | Internal Medicine | Southfield, MI | $121.84 | 1 |
| , MD | Hematology & Oncology | Flint, MI | $121.84 | 1 |
| , MD | Hematology & Oncology | Royal Oak, MI | $121.84 | 1 |
| , MD | Hematology & Oncology | Henderson, NV | $116.68 | 1 |
| , MD | Medical Oncology | Las Vegas, NV | $116.68 | 1 |
| , MD | Cardiovascular Disease | Las Vegas, NV | $116.68 | 1 |
| , M.D | Internal Medicine | Tulsa, OK | $109.54 | 1 |
| , MD | Hematology & Oncology | Hershey, PA | $104.16 | 1 |
| , M.D | Hematology & Oncology | Clermont, FL | $100.92 | 1 |
| , M.D | Neuromusculoskeletal Medicine, Sports Medicine | Bradenton, FL | $100.92 | 1 |
| , MD | Obesity Medicine | Tampa, FL | $100.92 | 1 |
| , MD | Medical Oncology | Kissimmee, FL | $100.92 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $33.4M
- Novartis Pharma AG $118,093
Product Information
- Type Drug
- Total Payments $33.5M
- Total Doctors 69
- Transactions 384
About GLEEVEC
GLEEVEC is a drug associated with $33.5M in payments to 69 healthcare providers, recorded across 384 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $1.6M was paid across 18 transactions to 5 doctors.
The most common payment nature for GLEEVEC is "Unspecified" ($33.2M, 99.0% of total).
GLEEVEC is associated with 7 research studies, including "AN OPEN LABEL MULTI CENTER IMATINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED IMATINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED IMATINIB TREATMENT" ($27.9M).